IMS Disease Insights – Alzheimer’s disease: Primary research & evidence-based data

Add bookmark

We respect your privacy, by clicking "Download Your Copy" you agree to having your details passed onto the sponsor who may promote similar products and services related to your area of interest subject to their privacy policy. You have the right to object. In addition, you will receive our e-newsletter, including information on related online learning opportunities. For further information on how we process and monitor your personal data, and information about your privacy and opt-out rights, click here.

Of the nine major pharmaceutical markets (i.e., US, UK, France, Germany, Italy, Spain, Japan, China, Brazil), IMS Health forecasts that the Alzheimer’s disease market will grow from $5.7 billion in 2012 to nearly $19 billion by 2022, making it one of the fastest growing disease areas in the industry. The US has the largest Alzheimer’s disease market and will see the greatest growth. However, the expanding elderly population in China, Japan, Brazil and Europe also presents significant market opportunity.

The expansion of the Alzheimer’s disease market will be led by novel disease-modifying agents targeting β-amyloid. Merck’s BACE1 inhibitor MK 8931 is the most promising agent in the pipeline, but near-term market expansion will be led by high-priced passive immunotherapies such as Eli Lilly’s solanezumab, Roche’s gantenerumab and crenezumab, and Eisai’s BAN2401. These two drug classes are forecast to capture 51% share of the total Alzheimer’s disease market by 2022.

 

IMS Health is pleased to share some of the key findings following a comprehensive study of the Alzheimer’s market, now published in our IMS Disease Insights report, part of a brand new series of disease-specific reports analyzing and forecasting the 10-year commercial outlook of the disease, for the USA, EU5, Japan, and 2 emerging markets, Brazil and China – to 2022.

RECOMMENDED